The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent
暂无分享,去创建一个
[1] V. Ferrans,et al. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells. , 2000, The Journal of pharmacology and experimental therapeutics.
[2] Jian-Mei Li,et al. Arresting developments in the cardiac myocyte cell cycle: role of cyclin-dependent kinase inhibitors. , 1998, Cardiovascular research.
[3] S. Grösch,et al. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. , 2004, Biochemical pharmacology.
[4] S. Kulp,et al. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. , 2004, Molecular cancer therapeutics.
[5] C. Dai,et al. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell‐cycle arrest, caspase‐3 activation, and downregulation of Cox‐2 expression and are synergistic with hydroxyurea or imatinib , 2006, American journal of hematology.
[6] N. Davies,et al. Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib , 2000, Clinical pharmacokinetics.
[7] W. Allan,et al. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. , 2001, Molecular pharmacology.
[8] M. Butler,et al. The effect of the catalytic topoisomerase II inhibitor dexrazoxane (ICRF-187) on CC9C10 hybridoma viability and productivity , 2001, Cytotechnology.
[9] Xinxin Guo,et al. Anthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes* , 2004, Journal of Biological Chemistry.
[10] P. Reddanna,et al. Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. , 2005, Cancer letters.
[11] Dairong Wang,et al. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. , 2005, Current opinion in pharmacology.
[12] A. Gerdes,et al. Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. , 1996, Journal of molecular and cellular cardiology.
[13] G. Berry,et al. Cardiac Safety of Pegylated Liposomal Doxorubicin (Doxil®/Caelyx®) Demonstrated by Endomyocardial Biopsy in Patients with Advanced Malignancies , 2004, Cancer investigation.
[14] S. Papa,et al. Arachidonic acid interaction with the mitochondrial electron transport chain promotes reactive oxygen species generation. , 1999, Free radical biology & medicine.
[15] G. Sokol,et al. The Cyclooxygenase-2 Inhibitor Celecoxib Is a Potent Inhibitor of Human Carbonic Anhydrase II , 2004, Inflammation.
[16] Xuli Wu,et al. Cytotoxicity of a non-cyclooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells. , 2006, Lung cancer.
[17] A. K. Jarvis,et al. 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. , 1997, The American journal of physiology.
[18] H Perrier,et al. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. , 1999, The Journal of pharmacology and experimental therapeutics.
[19] J. Emberson,et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.
[20] Garret A FitzGerald,et al. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. , 2005, The Journal of clinical investigation.
[21] Y. O’Malley,et al. Direct oxidation of 2',7'-dichlorodihydrofluorescein by pyocyanin and other redox-active compounds independent of reactive oxygen species production. , 2004, Free radical biology & medicine.
[22] J. Mitchell,et al. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs , 2006, Nature Reviews Drug Discovery.
[23] B. Hasinoff,et al. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. , 2003, Free radical biology & medicine.
[24] Scott D. Solomon,et al. Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005 .
[25] D. Fitzgerald,et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. , 2001, The Journal of clinical investigation.
[26] N. Davies,et al. Pharmacokinetics of Rofecoxib , 2003, Clinical pharmacokinetics.
[27] Sharon R. Adderley,et al. Oxidative Damage of Cardiomyocytes Is Limited by Extracellular Regulated Kinases 1/2-mediated Induction of Cyclooxygenase-2* , 1999, The Journal of Biological Chemistry.
[28] E. Fosslien. Cardiovascular complications of non-steroidal anti-inflammatory drugs. , 2005, Annals of clinical and laboratory science.